Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial (NCT07200830)
Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study is for patients with hormone resistant prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Hormone resistant prostate cancer often has many cells containing a protein called prostate-specific membrane antigen (PSMA) on their surface. The normal cells in the prostate do not normally express as much PSMA protein on their surface as cancer cells. Lutetium 177 Lu PSMA RLT binds to the PSMA protein on the tumor cells. It builds up in these cells and gives off radiation that may kill them. Typically, this medication is given at the same dose every 6 weeks for up to 6 doses. In this trial, researchers want to see if treatment following the first two doses of lutetium 177 Lu PSMA RLT can be delayed until there is evidence of disease activity. This may be an effective way to improve quality of life without decreasing lifespan in patients with advanced prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Providence Alaska Medical Center — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (112 Sites)
Showing the first 25 of 112 sites.
- Providence Alaska Medical Center — Anchorage, Alaska
- AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- City of Hope at Irvine Lennar — Irvine, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- CTCA at Southeastern Regional Medical Center — Newnan, Georgia
- Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
- Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
- Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
- Northwestern University — Chicago, Illinois
- Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- SSM Health Good Samaritan — Mount Vernon, Illinois
- Cancer Care Center of O'Fallon — O'Fallon, Illinois
- HSHS Saint Elizabeth's Hospital — O'Fallon, Illinois
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
- Midwestern Regional Medical Center — Zion, Illinois
- Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
📞 Contact the Study Coordinator
Phone: (773) 702-9171
Email: GUprotocols@alliancenctn.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-Resistant Prostate Carcinoma
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study — Seattle, Washington
- Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer — Ann Arbor, Michigan
- Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease — San Francisco, California
- Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer — Seattle, Washington
- SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy — Ann Arbor, Michigan
Explore by condition: All Metastatic Castration-Resistant Prostate Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.